Prevention

New anti-obesity drugs are closing gap between dieting and bariatric surgery

The Weight Wellness Program at UT Southwestern includes physicians, dietitians, and psychologists who approach obesity as a complex condition. Treatment often includes anti-obesity medications that help our patients focus on creating sustainable behaviors that support a healthy weight and lifestyle.

Time and again, the mantra “eat less and move more” has proven ineffective – and even counterproductive – for patients battling chronic weight problems and medical complications of obesity.

But a new spin on a class of diabetes medications is closing the gap between the two ends of the obesity treatment spectrum: lifestyle modification and bariatric surgery.

Semaglutide (Wegovy™) is the latest glucagon-like peptide-1 (GLP-1) receptor agonist drug to be approved by the U.S. Food and Drug Administration (FDA) as an adjunct to lifestyle changes for weight management in people with obesity or overweight – with a related medical complication such as high blood pressure. Semaglutide joins liraglutide (Saxenda), which is another GLP-1 receptor agonist that was FDA-approved for weight management in 2014.

GLP-1 receptor agonist medications can help you to lose weight in two ways:

  • Making the stomach empty slower – you’ll feel satisfied with smaller amounts of food, which helps you eat less and create a calorie deficit that can lead to weight loss.
  • Signaling the brain there is food in the stomach, which helps decrease appetite and cravings. This helps you to make more consistent choices that are aligned with your body’s needs.

In clinical trials of Wegovy as an adjunct to lifestyle modification, participants lost 15 percent of their body weight on average – with more than half the people treated with Wegovy losing more than 15 percent of their starting weight. That’s approximately 45 lbs. for a 300-pound patient – up to five times the average weight loss seen with traditional diet and exercise plans.

Patients in UT Southwestern’s Weight Wellness Program often exceed these weight loss results. Our team of physicians, dietitians, and psychologists approaches obesity as a complex condition that requires patient-centered care. Anti-obesity medications help our patients focus on creating sustainable behaviors that support a healthy weight and lifestyle, without the distractions of hunger and cravings.

Treatment plans, medications and procedures are selected based an individual’s situation and underlying health conditions. For example, weight loss medications like GLP-1 receptor agonists help to improve blood sugar, blood pressure, and fatty liver. Achieving a healthier weight can decrease the risk of complications associated with obesity, such as diabetes, fatty liver disease, sleep apnea, heart disease, depression, joint pain, and certain cancers.

More than 70 percent of U.S. adults have overweight or obesity. However, anti-obesity medications are prescribed to just 2 percent of eligible people due to concerns about safety or effectiveness, lack of healthcare provider training in weight management, and toxic stigma that portrays obesity as a lack of will-power. Advising a patient with obesity to simply “eat less and exercise more” is like telling a patient with depression to “cheer up.” It’s ineffective and often hurtful, particularly with the added stress of the pandemic.

Many centers simply recommend supplements, meal replacements, or bariatric surgery without much individualized care or medications beyond older stimulants. In our program, GLP-1 receptor agonist medications are one of many treatment options that can help position you for success.

How GLP-1 receptor agonist drugs work for weight loss

GLP-1 receptor agonists mimic a protein of the same name that is made naturally in the intestines when we eat. When used for weight management, these medications pump the brakes on our appetites and the rate at which food exits the stomach. As a result, we eat less because we are thinking less about food, and we are satisfied with smaller portions – even if we weren’t overeating.

GLP-1 receptor agonist medications make the stomach empty slower and signal the brain that you are full, reducing cravings. They can also help improve fatty liver.

GLP-1 receptor agonist medications were originally developed to treat type 2 diabetes and were found to cause weight loss while also decreasing the risk of cardiovascular event like heart attacks and strokes in people with diabetes. These medications are not insulin, and you don’t have to monitor your blood sugars unless directed by your healthcare team.

For people with chronic obesity and cardiovascular complications, GLP-1 receptor agonists are preferred to amphetamine-based therapies like phentermine, which can worsen blood pressure, heart rate, anxiety, and insomnia.

While any doctor can prescribe GLP-1 receptor agonists, primary care providers are often not familiar with prescribing these drugs. Starting at too high of a dose or increasing the dose too quickly can lead to symptoms such as indigestion, nausea, vomiting, diarrhea, or constipation. You will have better outcomes by working with a team of obesity management experts who can help you use these medications to create new, healthy, and sustainable habits.

About the UTSW Weight Wellness Program

We are the only academic medical center in North Texas with a dedicated, multidisciplinary weight management team of obesity medicine physicians, advanced practice providers, dietitians, and mental health professionals. Our specialists empower patients with evidence-based strategies to engage in their overall health and achieve personal wellness goals.

You won’t hear us tell you to start a fad diet or aim for a specific body weight. Instead, we help you create a plan that is aligned with your long-term health and wellness goals. To do this, we partner with other specialists and your primary care provider to recommend appropriate lifestyle plans (including mental health and physical therapy), medications, and procedures so you can start feeling healthier and more comfortable in your own skin.

How to join and next steps

Because so many of our patients have successful outcomes, new appointments are generally scheduled six to 12 months in advance. Getting into our scheduling system is the first step. Call 214-645-2800 to schedule an appointment.

Take these action items to give yourself a head start:

  • Ask your doctor to refer you to a dietitian. A nutrition professional can help you find healthy, convenient foods aligned with your body’s needs. Optimizing your diet can be the first step in managing health and improving energy levels.
  • Tend to your mental health. Body weight and your ability to look after yourself can be influenced by stress, isolation, depression, anxiety, or feelings related to life events. Seeing a counselor or therapist can help you understand and process some of these barriers to living your best life.
  • Surround yourself with positivity. Join a support group, reconnect with your spiritual side, or spend time with family and loved ones – remind yourself that better health is worth the journey. Make a list of why your health is import to you, such as traveling or being independent, to help make a plan that aligns with your goals.

Weight-loss drug targets fat that endangers heart

According to a new study published by UTSW preventive cardiologist Parag Joshi, M.D., a once-daily dose of liraglutide combined with lifestyle interventions significantly lowered two types of fat that endanger heart health.

Learn more

Obesity, diabetes, and fatty liver disease

GLP-1 receptor agonists have been used for years to treat type 2 diabetes. In the last decade, the FDA has recognized their effectiveness as anti-obesity medications. Liraglutide (Saxenda) was FDA-approved in 2014 for weight-management in adults with overweight and obesity. In 2020, Saxenda was approved for children and adolescents 12 years and older with obesity or overweight with an associated health problem, such as high blood pressure.

Fighting fatty liver disease

In the last couple years, nonalcoholic fatty liver disease (NAFLD) has become the No. 1 reason U.S. women are added to the liver transplant list and the second-leading cause for all adults. UT Southwestern is conducting clinical studies to find and improve medication options for NAFLD.

Learn more

Other GLP-1 receptor agonists that are FDA-approved to treat type 2 diabetes and may lead to weight loss include:

Many diabetes medications and insulin reduce blood sugars but also contribute to weight gain. However, GLP-1 receptor agonists help to lower blood sugars in people with diabetes – without causing low blood sugars in people who don’t have diabetes.

Weight loss can also help to control and prevent non-alcoholic fatty liver disease (NAFLD) – another condition associated with obesity. Although not FDA-approved for the treatment of NAFLD, GLP-1 receptor agonists – in conjunction with other lifestyle changes – can help people with fatty liver achieve clinically meaningful weight loss and better health. Fatty liver disease can cause liver inflammation and damage that can progress into cirrhosis of the liver. One-third of U.S. adults have NAFLD, and 20 percent of people with obesity develop non-alcoholic steatohepatitis, a more serious form of the disease.

The future of obesity treatment

UT Southwestern plans to open a state-of-the-art interdisciplinary obesity management center at Texas Health Dallas, where patients can see obesity medicine specialists, bariatric surgeons, and plastic surgeons in a single location.

We have also created an Endobariatric Program, where patients can undergo new minimally invasive bariatric procedures like the endoscopic sleeve gastroplasty. This less-invasive version of the sleeve gastrectomy bariatric surgery is performed by advanced gastroenterologists and does not require traditional surgery or cutting the skin. Endobariatric procedures can produce significant weight loss with a faster and more comfortable recovery that traditional surgeries. These types of procedures can also treat weight regain in people with a history of bariatric surgery who have regained weight.

Compared with lifestyle changes or older anti-obesity medications, our study in Obesity showed that GLP-1 receptor agonist regimens are superior for treating weight regain after bariatric surgery. We see many patients who underwent bariatric surgery years ago and have experienced weight regain. In these instances, we work on lifestyle modification and collaborate with our endobariatric colleagues to provide the latest minimally invasive techniques for managing weight regain, while also using medications like GLP-1 receptor agonists to help people achieve the healthiest weight possible.

Obesity is a culmination of factors that span genetics, lifestyle, environment, and physical and mental health. After years of living with obesity, achieving a healthier lifestyle without individualized support can be difficult, if not impossible.

While the foundations of a healthy lifestyle will always begin with diet and exercise, and bariatric procedures can be the right choice for patients with the chronic health issues associated with severe obesity, GLP-1 receptor agonists provide another safe, effective, and measured approach.

For information about the UTSW Weight Wellness Program, call 214-645-2800 or request an appointment online.

Eating and Staying Healthy During the Pandemic

Dr. Jaime Almandoz, a weight management expert, and registered dietitian Susan Rodder appeared on the Nov. 13, 2020, episode of UTSW's 'What to Know' to share strategies about how to eat healthy during the pandemic while maintaining your family’s well-being.

Watch More Episodes of What to Know